A detailed history of Granite Group Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Granite Group Advisors, LLC holds 25,489 shares of GILD stock, worth $2.36 Million. This represents 1.37% of its overall portfolio holdings.

Number of Shares
25,489
Previous 25,825 1.3%
Holding current value
$2.36 Million
Previous $1.77 Billion 20.61%
% of portfolio
1.37%
Previous 1.34%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$66.59 - $83.99 $22,374 - $28,220
-336 Reduced 1.3%
25,489 $2.14 Billion
Q2 2024

Jul 23, 2024

SELL
$63.15 - $72.88 $22,481 - $25,945
-356 Reduced 1.36%
25,825 $1.77 Billion
Q1 2024

May 31, 2024

SELL
$71.58 - $87.29 $9,591 - $11,696
-134 Reduced 0.51%
26,181 $1.92 Billion
Q4 2023

Apr 03, 2024

BUY
$73.27 - $83.09 $1.93 Million - $2.19 Million
26,315 New
26,315 $1.98 Billion

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Granite Group Advisors, LLC Portfolio

Follow Granite Group Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Group Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Group Advisors, LLC with notifications on news.